AFT Pharmaceuticals starts to license Maxigesic IV with deal in South Korea

Company News

by Anna Napoli

AFT Pharmaceuticals (ASX:AFP) has started the commercialization program for its patented Maxigesic intravenous formulation (IV).

The company has signed a licensing agreement with South Korean company, Kyongbo Pharmaceutical

The Maxigesic IV infusion has been developed as a line extension to Maxigesic tablets for use post-operativly in hospitals.

A major phase 3 study clinical trial conducted in Texas and Maryland found that Maxigesic IV provided significantly better pain relief than either paracetamol or ibuprofen.

Shares in AFT Pharmaceuticals (ASX:AFP) are Flat at $2.05.




Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.